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A B S T R A C T
Objective: This study was conducted to evaluate the eﬀects of omega-3 fatty acids and vitamin E co-supple-
mentation on gene expression related to inﬂammation, insulin and lipid in subjects with Parkinson's disease
(PD).
Patients and methods: This randomized, double-blind, placebo-controlled clinical trial was performed in 40
subjects with PD. Participants were randomly allocated into two groups to take either 1000mg/day of omega-3
fatty acids from ﬂaxseed oil plus 400 IU/day of vitamin E supplements or placebo (n=20 each group) for 12
weeks. Gene expression related to inﬂammation, insulin and lipid were quantiﬁed in peripheral blood mono-
nuclear cells (PBMC) of PD patients with RT-PCR method.
Results: After the 12-week intervention, compared with the placebo, omega-3 fatty acids and vitamin E co-
supplementation downregulated gene expression of tumor necrosis factor alpha (TNF-α) (P= 0.002) in PBMC of
subjects with PD. In addition, omega-3 fatty acids and vitamin E co-supplementation upregulated peroxisome
proliferator-activated receptor gamma (PPAR-γ) (P= 0.03), and downregulated oxidized low-density lipopro-
tein receptor (LDLR) (P=0.002) in PBMC of subjects with PD compared with the placebo. We did not observe
any signiﬁcant eﬀect of omega-3 fatty acids and vitamin E co-supplementation on gene expression of interleukin-
1 (IL-1) and IL-8 in PBMC of patients with PD.
Conclusions: Overall, omega-3 fatty acids and vitamin E co-supplementation for 12 weeks in PD patients sig-
niﬁcantly improved gene expression of TNF-α, PPAR-γ and LDLR, but did not aﬀect IL-1 and IL-8.
1. Introduction
Parkinson's disease (PD) is a progressive disorder which related to
motor symptoms such as bradykinesia, rigidity and tremor, and non-
motor symptoms such as depression and cognitive disorder [1]. Pre-
vious studies have indicated that elevated levels of inﬂammatory cy-
tokines including tumor necrosis factor alpha (TNF-α) and interluekin-1
(IL-1) in patients with PD play a pivotal role in the pathogenesis of PD
[2,3]. In addition, modulation of peroxisomalprolifera tor-activated
receptor gamma (PPAR-γ) activity leads to neuroprotective eﬀects on
oxidative stress, apoptosis and neuroinﬂammation in PD [4].
We have previously shown that omega-3 fatty acids and vitamin E
co-supplementation intake for 12 weeks among patients with PD had
beneﬁt eﬀects on Uniﬁed Parkinson's disease rating stage, insulin me-
tabolism, high-sensitivity C-reactive protein, glutathione and total an-
tioxidant capacity [5]. Few studies have reported the eﬀects of omega-3
fatty acids and vitamin E supplementation on gene expression related to
metabolic proﬁles in patients without PD. For example, in a study by
Chen et al. [6], it was observed that the administration of omega-3 fatty
acids signiﬁcantly decreased TNF-α and IL-1β expression in experi-
mental traumatic brain injury. In another study by Monteiro et al. [7], it
was reported that vitamin E supplementation to rats with alcoholic
chronic pancreatitis resulted in a signiﬁcant decrease in gene expres-
sion of TNF-α. In addition, our previous study have supported that
omega-3 fatty acids and vitamin E co-supplementation for 12 weeks
among patients with polycystic ovary syndrome (PCOS) decreased gene
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expression of lipoprotein(a) [LP(a)] and low-density lipoprotein re-
ceptor (LDLR) [8]. However, no signiﬁcant change in TNF-α expression
was observed following the supplementation of omega-3 fatty acids for
12 weeks among subjects with insulin resistance [9].
Theses evidence suggests the importance of co-supplementation of
omega-3 fatty acids and vitamin E in patients with PD. In addition, co-
supplementation of omega-3 fatty acids and vitamin E might have a
strong synergistic eﬀect on gene expression related to inﬂammation,
insulin and lipid. To our knowledge, there was no study on the eﬀects of
omega-3 fatty acids and vitamin E co-supplementation on gene ex-
pression related to inﬂammation, insulin and lipid in patients with PD.
The aim of the current study was to evaluate the eﬀects of omega-3
fatty acids and vitamin E co-supplementation on gene expression re-
lated to inﬂammation, insulin and lipid in patients with PD.
2. Patients and methods
2.1. Participants
This monocentric randomized, double-blind, placebo-controlled
clinical trial, registered in the Iranian website for registration of clinical
trials (http://www.irct.ir: IRCT2017061234497N1), was conducted
among population with PD, aged 50–80 years old diagnosed according
to clinical diagnostic criteria of the UK PD Society Brain Bank [10]
referred to the Shahid Beheshti Clinic in Kashan, Iran, between April
2017 and August 2017. This study was performed according to Good
Clinical Practice guidelines and the study protocol was approved by the
research ethics committee of Kashan University of Medical Sciences
(KAUMS), Kashan, and Iran. Written informed consent was obtained
from all subjects before the study. Exclusion criteria were subjects who
were already taking omega-3 and/or vitamin E, taking DDP4 inhibitors,
statins and anti-inﬂammatory drugs, had depression and had severe
psychosis.
2.2. Study design
Subjects were randomly allocated into two groups to take either
1000mg of omega-3 fatty acids from ﬂaxseed oil plus 400 IU of vitamin
E supplements or placebo (n=20 each group) for 12 weeks. Subjects
were requested to consume supplements or placebo after lunch. Omega-
3, vitamin E supplements and placebos were manufactured by Barij
Essence Pharmaceutical Company (Kashan, Iran). The placebo (par-
aﬃn) was identical in color, shape, size and package to the omega-3
fatty acids plus vitamin E capsules. Subjects were requested not to
change their ordinary physical activity during the 12-week trial.
Randomization was conducted by a computer-generated and centrally
administered procedure. Patients, investigators, clinical site staﬀ and
laboratory staﬀ were all masked to treatment assignment throughout
the study.
2.3. Treatment adherence
The consumption of supplements and placebos during the study was
checked by asking people to return the medication containers and re-
ceiving brief daily cell phone reminders to take the supplements by
participants.
2.4. Assessment of outcomes
The primary outcomes were gene expression related to in-
ﬂammatory cytokines. The secondary outcomes were gene expression
related to insulin and lipid.
2.5. Clinical evaluation at entry
To evaluate clinical signs, UPDRS total score as well as 4 subscores
were used [11].
2.6. Isolation of lymphocyte, RNA extraction and cDNA synthesis
Twenty milliliters overnight fasting blood samples were collected at
baseline and end-of-trial between 6.5 and 7 a.m at central reference
laboratory of Kashan, and Iran. Lymphocytes were isolated using 50%
percoll solution (Sigma-Aldrich, Dorset, UK) gradient by centrifugation
for 20min and 3000 rpm at 4 °C [12]. Total RNA was extracted based
on acid guanidinium-phenol-chloroform procedure using RNX™-plus
reagent (Cinnacolon, Tehran, Iran) according to the manufacturer's
instructions. RNAs was treated with DNAase I (Fermentas, Lithuania)
for the elimination of any genomic DNA contamination. Concentration,
integration and purity of RNA samples were determined by spectro-
metry and gel electrophoresis. 3 μg of total RNA was used for cDNA
synthesis with random hexamer and oligo (dT) 18 primers through
RevertAid™ Reverse Transcriptase (Fermantase, Canada) in total 20 μl
reaction mixture [12].
2.7. Real-time PCR analysis
Appropriate primers for IL-1, IL-8, TNF-α, PPAR-γ and LDLR, and
glyceraldehyde-3 phosphate dehydrogenase-as an internal control-were
designed (Table 1). Quantitative Real-time PCR was performed by the
LightCycler® 96 sequence detection systems (Roche Diagnostics, Rotk-
reuz, Switzerland) using 4 μl of 5×EVA GREEN I master mix (Salise
Biodyne, Japan), 10 ng cDNA, 200 nM of each forward and reverse
primers in ﬁnal volume of 20 μl. The PCR was performed through the
following instruction: an initial denaturation at 95 °C for 10min, fol-
lowed by 40 cycles of denaturation at 95 °C for 10 s, annealing at
54–62.1 °C for 15 s and extension at 72 °C for 30 s. The speciﬁcity of
PCR products was evaluated by 1.5% agarose gel electrophoresis and
melting curve analysis. All experiments were performed at least in tri-
plicate.
2.8. Sample size
To determine the sample size, we used a randomized clinical trial
sample size formula where type one (α) error was considered as 5% and
the study power as 80%. We considered TNF-α as the main outcome of
the study; therefore, we needed 16 subjects in each group. Assuming a
dropout of 4 participants per group, the ﬁnal sample size was de-
termined to be 20 participants per group.
Table 1
Speciﬁc primers used for real-time quantitative PCR.
Gene Primer Product
size (bp)
Annealing
temperature (C)
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
IL-1 F: GCTTCTCTCTGGTCCTTGG 174 56
R: AGGGCAGGGTAGAGAAGAG
IL-8 F: GCAGAGGGTTGTGGAGAAGT 150 56
R: ACCCTACAACAGACCCACAC
TNF-α F: GTCAACCTCCTCTCTGCCAT 188 52
R: CCAAAGTAGACCTGCCCAGA
PPAR-γ F: ATGACAGACCTCAGACAGATTG 210 54
R: AATGTTGGCAGTGGCTCAG
LDLR F: ACTTACGGACAGACAGACAG 223 57
R: GGCCACACATCCCATGATTC
GAPDH, glyceraldehyde-3-Phosphate dehydrogenase; IL-1, interleukin-1; IL-8,
interleukin-8; LDLR, oxidized low-density lipoprotein receptor; PPAR-γ, per-
oxisome proliferator-activated receptor gamma; TNF-α, tumor necrosis factor
alpha.
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2.9. Statistical methods
To determine whether the study variables were normally distributed
or not, we used the Kolmogorov-Smirnov test. To detect diﬀerences in
anthropometric measures, and macro- and micro-nutrient intakes, we
used Student’s t-test to independent samples. Multiple linear regression
models were used to evaluate treatment impacts on study outcomes
after adjusting for confounding parameters including; age and duration
of disease. The P-value<0.05 were considered statistically signiﬁcant.
All statistical analyses used the Statistical Package for Social Science
version 18 (SPSS Inc., Chicago, Illinois, USA).
3. Results
Forty subjects [omega-3 and vitamin E (n= 20) and placebo
(n=20)] completed the trial (Fig. 1).
Mean age, height, weight and BMI at week 0 and week 12 of the
intervention were not diﬀerent between the two groups (Table 2). After
12 weeks’ intervention, compared with the placebo, omega-3 and vi-
tamin E co-supplementation led to a signiﬁcant improvement in UPDRS
(-3.4 ± 8.1 vs.+ 7.1 ± 14.6, P= 0.008). Omega-3 and vitamin E co-
supplementation signiﬁcantly improved UPDRS-part I (−0.1 ± 1.0
vs.+ 1.8 ± 1.4, P=0.01) compared with the placebo, but did not
aﬀect other parts of UPDRS score.
We found no signiﬁcant diﬀerence in mean macro- and micro-
nutrient intakes between the two groups (Data not shown).
After the 12-week intervention, compared with the placebo, omega-
3 fatty acids and vitamin E co-supplementation downregulated gene
expression of TNF-α (P= 0.002) in PBMC of subjects with PD (Fig. 2).
We did not observe any signiﬁcant eﬀect of omega-3 fatty acids and
vitamin E co-supplementation on gene expression of interleukin-1 (IL-1)
and IL-8 in PBMC of patients with PD.
Omega-3 fatty acids and vitamin E co-supplementation upregulated
PPAR-γ (P=0.03), and downregulated LDLR (P=0.002) in PBMC of
subjects with PD compared with the placebo (Fig. 3).
Fig. 1. Summary of patient ﬂow diagram.
Table 2
General characteristics of study participants.
Placebo group
(n=20)
Omega-3 and vitamin E
group (n= 20)
Pa
Age (y) 67.5 ± 9.8 65.5 ± 8.3 0.46
Height (cm) 166.2 ± 6.0 165.4 ± 7.1 0.72
Weight at study baseline
(kg)
68.7 ± 6.3 70.1 ± 13.3 0.69
Weight at end-of-trial (kg) 68.5 ± 5.9 70.2 ± 12.9 0.60
Weight change (kg) −0.2 ± 1.1 0.1 ± 0.8 0.26
BMI at study baseline (kg/
m2)
24.9 ± 2.3 25.7 ± 5.2 0.53
BMI at end-of-trial (kg/m2) 24.8 ± 2.1 25.8 ± 5.1 0.46
BMI change (kg/m2) −0.1 ± 0.4 0.1 ± 0.3 0.26
Disease duration (y) 7.5 ± 4.6 6.3 ± 2.9 0.35
Levodopa dose equivalency
(mg/d)
810 ± 360 815 ± 393 0.90
UPDRS total
Baseline 42.9 ± 15.8 44.3 ± 18.1 0.80
End-of-trial 50.0 ± 16.1 40.8 ± 16.3 0.08
Change 7.1 ± 14.6 −3.4 ± 8.1 0.008
UPDRS part I
Baseline 4.3 ± 2 3.3 ± 2.3 0.10
End-of-trial 6.1 ± 2.3 3.1 ± 2.1 0.01
Change 1.8 ± 1.4 −0.1 ± 1 0.01
UPDRS part II
Baseline 12.9 ± 4.9 12.7 ± 6.3 0.90
End-of-trial 13.9 ± 6.1 11.9 ± 5.1 0.20
Change 1.0 ± 3.4 −0.8 ± 2.4 0.05
UPDRS part III
Baseline 21.6 ± 9.4 23.7 ± 11.1 0.50
End-of-trial 24.7 ± 9.3 21.8 ± 9.7 0.31
Change 3.1 ± 9.8 −1.9 ± 5.5 0.05
UPDRS part IV
Baseline 4.1 ± 2.9 3.5 ± 2.5 0.52
End-of-trial 5.2 ± 3.6 3.1 ± 2.2 0.02
Change 1.1 ± 4.3 −0.5 ± 2.7 0.11
Data are means ± SDs.
a Obtained from independent t-test.
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4. Discussion
In the current study, we evaluated the eﬀects of omega-3 and vi-
tamin E co-supplementation on gene expression related to inﬂamma-
tion, insulin and lipid in populations with PD. We found that omega-3
fatty acids and vitamin E co-supplementation for 12 weeks in PD pa-
tients signiﬁcantly improved gene expression of TNF-α, PPAR-γ and
LDLR, but did not aﬀect IL-1 and IL-8. To our knowledge, this study is
the ﬁrst report of the eﬀects of omega-3 and vitamin E co-supple-
mentation on gene expression related to inﬂammation, insulin and lipid
in populations with PD.
In the current study, we found that omega-3 and vitamin E co-
supplementation to subjects with PD for 12 weeks signiﬁcantly de-
creased UPDRS part I compared with the placebo, but did not aﬀect
other parts of UPDRS. Some studies have evaluated the eﬀects of
omega-3 or vitamin E supplementation on dementia and psychosis in
patients without PD. In a study by Freund-Levi et al. [13], omega-3
fatty acid treatment [1.7 g of docosahexaenoic acid (DHA) and 0.6 g of
eicosapentaenoic acid (EPA)] for 6 months in patients with mild Alz-
heimer's disease (AD) signiﬁcantly improved cognitive function. In
addition, omega-3 fatty acid supplementation at a dosage of 1.8 g/day
for 24 weeks to subjects with mild cognitive impairment had favorable
eﬀects on cognition [14]. Also, administration of 2000 IU/day vitamin
E to patients with AD led to slower functional decline [15]. In another
study, taking omega-3 fatty acid supplements at a dosage of 1.2 g/day
for 12 weeks by people with borderline personality disorder sig-
niﬁcantly improved psychotic disorders [16]. Furthermore, co-admin-
istration of omega-3 fatty acid (1000mg/day) and vitamin E (400 IU/
day) for 12 weeks to subjects with PCOS improved psychotic para-
meters [17]. Supplementation with a combination of omega-3 plus vi-
tamins E and C also improved psychotic symptoms in patients with
schizophrenia [18]. Omega-3 fatty acid intake may improve dementia
and psychosis symptoms through facilitating membrane translocation/
activation of Akt and a downstream eﬀector in the phosphoinositide 3-
kinase pathway [19]. In addition, vitamin E intake may improve cog-
nitive function due to protective eﬀect on dopamine-induced cell death
and reactive oxygen species production [20].
Our study supported that omega-3 and vitamin E co-supplementa-
tion to subjects with PD for 12 weeks signiﬁcantly decreased gene ex-
pression of TNF-α compared with the placebo, but did not aﬀect IL-1
and IL-8. However, data on the eﬀects of omega-3 and vitamin E co-
supplementation on gene expression related to inﬂammation in subjects
with PD are scarce. In a study by Abdolahi et al. [21], it was observed
that omega-3 fatty acids and nano-curcumin co-supplementation for 2
months to migraine patients downregulated gene expression of TNF-α,
and decreased circulating levels of TNF-α in a synergistic manner. In
addition, anti-inﬂammatory eﬀect of omega-3 has been reported by
other researchers, when omega-3 antagonize the nuclear factor kappa B
signaling pathway, and suppress the expression of inﬂammatory genes
downstream of NF-κB [22,23]. We also previously have showed that
ﬂaxseed oil supplementation at a dosage of 2 g/day for 12 weeks to
overweight diabetic patients with coronary heart disease signiﬁcantly
improved gene expression of IL-1 and TNF-α, but did not aﬀect gene
expression of IL-8 and transforming growth factor beta [24]. Further-
more, vitamin E supplementation at a dosage of 400 IU/day for 12
weeks to subjects with implantation failure had favorable eﬀects on
Fig. 2. Eﬀect of a 12-week supplementation with combined omega-3 and vitamin E or placebo on gene expression of IL-1, IL-8 and TNF-α in blood mononuclear cells
of patients with Parkinson’s disease.
P-value obtained from multiple linear regression models adjusted based on age and duration of disease.
Fig. 3. Eﬀect of a 12-week supple-
mentation with combined omega-3 and
vitamin E or placebo on gene expres-
sion of PPAR-γ and LDLR in blood
mononuclear cells of patients with
Parkinson's disease.
P-value obtained from multiple linear
regression models adjusted based on
age and duration of disease.
IL-1, interleukin-1; IL-8, interleukin-8;
LDLR, oxidized low-density lipopro-
tein; PPAR-γ, peroxisome proliferator-
activated receptor gamma; TNF-α,
tumor necrosis factor alpha.
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gene expression of IL-1, and TNF-α [25]. In another study, vitamin E
administration had anti-inﬂammatory and beneﬁcial eﬀects on the
pancreatic gene expression of some inﬂammatory factors in rats with
alcoholic chronic pancreatitis [26]. However, there were no additive
eﬀects of omega-3 and vitamin E co-supplementation on serum levels of
pro-inﬂammatory cytokines in immune system-stimulated growing-
ﬁnishing pigs [27]. Increased inﬂammation both peripheral and neu-
roinﬂammation may result in immune responses in the brain [28].
Furthermore, a signiﬁcant elevation in the density of glial cells ex-
pressing TNF-α and IL-1 was observed in substantia nigra of PD subjects
[29], which in turn freely diﬀuse past the blood brain barrier into the
peripheral blood supply [30]. Therefore, omega-3 fatty acids and vi-
tamin E co-supplementation due to their beneﬁcial eﬀects on in-
ﬂammatory markers may be useful to control neurological symptoms in
population with PD.
The current study demonstrated that taking omega-3 and vitamin E
co-supplements by subjects with PD for 12 weeks signiﬁcantly in-
creased gene expression of PPAR-γ, and signiﬁcantly decreased LDLR
compared with the placebo. We have previously showed that taking
omega-3 from ﬂaxseed oil at a dosage of 1000mg twice a day for 12
weeks by patients with PCOS signiﬁcantly improved gene expression of
PPAR-γ and LDLR [31]. In addition, supplementation with 3.4 g/day of
EPA and DHA for 2–3 weeks upregulated gene expression levels of
PPAR-γ [32]. Similarly, vitamin E supplementation to a rabbit model
resulted in increasing gene expression of PPAR-γ [33]. Omega-3
(1000mg/day) and vitamin E (400 IU/day) co-supplementation for 12
weeks in PCOS women also improved gene expression of LDLR [8].
However, gene expression levels of PPAR-γ did not inﬂuence following
supplementation with 2400mg/day of ﬁsh oil containing 1450mg of
DHA and 400mg of EPA to subjects with type 2 diabetes mellitus for 8
weeks [34]. Furthermore, vitamin E supplementation for 6, 14 and 22
weeks in Apolipoprotein E knockout mice signiﬁcantly downregulated
gene expression of PPAR-γ [35]. PPAR-γ and its ligands have been
demonstrated as potential therapeutic targets for the treatment of
several pathological conditions linked to neuroinﬂammation within the
central nervous system [36]. In addition, PPAR-γ involve in diﬀer-
entiation, energetic metabolism, diabetes, carcinogenesis, athero-
sclerosis, inﬂammation, and neurodegeneration [37]. On the other
hand, increased gene expression of PPAR-γ improves insulin sensitivity,
owing to changes in the transcription and expression of genes inﬂuen-
cing carbohydrate and lipid metabolism [38]. Furthermore, increased
PPAR-γ activation can have additional eﬀects upon cellular physiology,
including anti-proliferative and anti-inﬂammatory [38].
Our study had few limitations. Firstly, due to budget limitations, we
did not evaluate measurements of fatty acids fractions at baseline and
after the 12-week intervention. In addition, we did not evaluate gene
expression related to oxidative stress.
Overall, omega-3 fatty acids and vitamin E co-supplementation for
12 weeks in PD patients signiﬁcantly improved gene expression of TNF-
α, PPAR-γ and LDLR, but did not aﬀect IL-1 and IL-8.
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